Pep-Therapy Raises €2.75 Million In Series A Financing To Advance Its Lead Candidate, Pep-010, Into The Clinic
Pep-Therapy Raises €2.75 Million In Series A Financing To Advance Its Lead Candidate, Pep-010, Into The Clinic
04/22/21, 7:11 AM
Location
parisMoney raised
€2.75 million
Round Type
series a
PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announces it has raised a €2.75 million in a Series A financing round. The financing was led by Italian Angels for Growth (IAG), with participation from Doorway, Magna Capital Partner (MCP) and Business Angels des Grandes Ecoles (BADGE) as well as existing investors Seventure Partners (Quadrivium 1 Seed Fund) and Dr. Bernard Majoie (former Chairman and CEO of Laboratoires Fournier).
Company Info
Location
paris, ile de france, france
Additional Info
PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company's innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.